8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 8, 2011

______________

Stellar Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

______________

Ontario, Canada	0-31198	Not Applicable
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

544 Egerton Street, London, Ontario, Canada, N5W 3Z8

(Address of Principal Executive Office) (Zip Code)

(519) 434-1540

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01       Regulation FD Disclosure

See Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Stellar Pharmaceuticals Engages Advisory Consultant for its Products in the United States Market

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.
By:	/s/ Arnold Tenney
	Arnold Tenney President and Chief Executive Officer

Date:  June 8, 2011

 3

EX-99.1

EXHIBIT 99.1

Press Release Source: Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals Engages Advisory Consultant for its Products in the United States Market

LONDON, ONTARIO – June 8, 2011 - Stellar Pharmaceuticals Inc. ("Stellar" or "Company") (OTCQB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced it has engaged the services of Advisory Associates, Inc. ("AAI"), as an advisory consultant.

Under the terms of the agreement, AAI will is charged with the task of locating leads and assisting in negotiating a license deal for the Company’s products, NeoVisc® and Uracyst® for the United States market.

Arnold Tenney, Interim President and CEO of Stellar stated, “I am pleased that we were able to enter into this agreement with AAI given its experience and proven track record in negotiating these types of deals. I look forward to working with AAI in securing license agreements for the Company’s products in this very important market.”

 “We at AAI are excited about working with the Stellar organization once again.  Urological and Osteoarthritis pharmaceutical treatments continue to experience significant growth in the U.S. as new therapies are developed for women’s health and an aging population.  Accordingly, NeoVisc® and Uracyst® have significant competitive advantages that make them compelling targeted therapies,” said Patrick D. Scrivens, Chief Executive Officer of AAI.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology:  NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall.  Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

For more information contact:

Stellar Pharmaceuticals Inc.  

Arnold Tenney – Interim President & CEO

800-639-0643 or 705-445-9505

OR

Advisory Associates, Inc.

Patrick Scrivens

703-442-5310